Market Research Industry Reports

Vertex Pharmaceuticals Inc (VRTX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Vertex Pharmaceuticals Inc (Vertex) is a biotechnology company that carries out the discovery, development and commercialization of transformative drugs for the treatment of serious and life-threatening diseases. The company product portfolio includes Orkambi (ivacaftor/lumacaftor) and Kalydeco (ivacaftor) for the treatment of cystic fibrosis (CF). Through its research and development (R&D) efforts, the company focuses on influenza, cancer, neurological diseases and disorders including pain and cystic fibrosis. Vertex has R&D centers and commercial offices in North America, South America, Europe and Australia. The company offers its products in the US, Europe, Australia and Canada. Vertex is headquartered in Boston, Massachusetts, the US.

Vertex Pharmaceuticals Inc (VRTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Vertex Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Vertex Pharma Acquires CTP-656 from Concert Pharma 13
Vertex Pharma Acquires Cystic Fibrosis Assets from AmorChem 15
Partnerships 16
Q-State Biosciences Enters into Agreement with Vertex Pharmaceuticals 16
X-Chem Enters into Agreement with Vertex Pharma 17
Vertex Pharma Enters into Research Collaboration with CRISPR Therapeutics 18
Vertex Pharma Enters into Co-Development Agreement with Parion Sciences 19
Licensing Agreements 20
Vertex Pharma Enters into Licensing Agreement with CRISPR Therapeutics 20
Merck Enters into Licensing Agreement with Vertex Pharma 21
Vertex Pharma Enters into Licensing Agreement with Moderna Therapeutics 22
Enterome Bioscience Enters into Licensing Agreement with Vertex Pharma 23
Vertex Pharma Enters into Licensing Agreement with BioAxone Biosciences for VX-210 24
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 25
EIP Pharma Enters into Licensing Agreement with Vertex Pharma 26
Asset Transactions 27
Trek Therapeutics Acquires Rights to Two Antiviral Inhibitors from Vertex Pharma 27
Spero Therapeutics Acquires Rights to Novel Gyrase Inhibitors from Vertex Pharma 28
Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million 29
Vertex Pharmaceuticals Inc - Key Competitors 30
Vertex Pharmaceuticals Inc - Key Employees 31
Vertex Pharmaceuticals Inc - Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 35
Financial Announcements 35
Apr 26, 2018: Vertex Reports First-Quarter 2018 Financial Results 35
Jan 31, 2018: Vertex Reports Full-Year and Fourth-Quarter 2017 Financial Results 37
Oct 25, 2017: Vertex Reports Third-Quarter 2017 Financial Results 40
Jul 26, 2017: Vertex Reports Second-Quarter 2017 Financial Results 43
Apr 27, 2017: Vertex Reports First-Quarter 2017 Financial Results 46
Jan 25, 2017: Vertex Reports Full-Year and Fourth-Quarter 2016 Financial Results 49
Corporate Communications 51
Jun 14, 2018: The Vertex Foundation and Employees Donate $1 Million Through Matching Gift Program 51
Mar 29, 2018: Vertex Pharmaceuticals Names Kimberly A. White As Senior Vice President And Chief Communications Officer 52
Feb 26, 2018: Vertex Names Reshma Kewalramani As Chief Medical Officer 53
Oct 17, 2017: Vertex Announces 10-Year, $500 Million Corporate Giving Commitment 54
Sep 06, 2017: Vertex Appoints Tom Graney as Senior Vice President and Chief Financial Officer 55
Jun 08, 2017: Vertex Names Dr. Alan Garber, Provost of Harvard University, to its Board of Directors 56
Government and Public Interest 57
Nov 01, 2017: Vertex Announces New $750,000 Program to Support the Work of the Next Generation of Cystic Fibrosis Researchers 57
May 04, 2017: Vertex Grants $1 Million to 15 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis 58
Product News 59
07/18/2017: Vertex Provides Update on VX-445 development program 59
Product Approvals 60
Jan 20, 2017: Concert Pharmaceuticals Receives FDA Orphan Drug Designation for CTP-656 for the Treatment of Cystic Fibrosis 60
Clinical Trials 61
Apr 26, 2018: Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis 61
Feb 21, 2018: Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis 63
Feb 01, 2018: Vertex Selects Next-Generation Corrector, VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis 64
Feb 01, 2018: Vertex Selects Next-Generation Corrector, VX-659, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis 66
Jul 18, 2017: Vertex Announces Positive Phase 2 Data from Triple Combination Regimen with VX-440 68
Jul 18, 2017: Vertex Announces Positive Phase I Data from Triple Combination Regimen with VX-659 70
Jan 17, 2017: Concert Pharmaceuticals Provides Further Details on CTP-656 Development in U.S. and Europe 72
Other Significant Developments 73
Jan 08, 2017: Vertex Provides Update on Business and Financial Performance and Research and Development Programs 73
Appendix 76
Methodology 76
About GlobalData 76
Contact Us 76
Disclaimer 76

List Of Tables

List of Tables
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vertex Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Vertex Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Vertex Pharma Acquires CTP-656 from Concert Pharma 13
Vertex Pharma Acquires Cystic Fibrosis Assets from AmorChem 15
Q-State Biosciences Enters into Agreement with Vertex Pharmaceuticals 16
X-Chem Enters into Agreement with Vertex Pharma 17
Vertex Pharma Enters into Research Collaboration with CRISPR Therapeutics 18
Vertex Pharma Enters into Co-Development Agreement with Parion Sciences 19
Vertex Pharma Enters into Licensing Agreement with CRISPR Therapeutics 20
Merck Enters into Licensing Agreement with Vertex Pharma 21
Vertex Pharma Enters into Licensing Agreement with Moderna Therapeutics 22
Enterome Bioscience Enters into Licensing Agreement with Vertex Pharma 23
Vertex Pharma Enters into Licensing Agreement with BioAxone Biosciences for VX-210 24
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 25
EIP Pharma Enters into Licensing Agreement with Vertex Pharma 26
Trek Therapeutics Acquires Rights to Two Antiviral Inhibitors from Vertex Pharma 27
Spero Therapeutics Acquires Rights to Novel Gyrase Inhibitors from Vertex Pharma 28
Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million 29
Vertex Pharmaceuticals Inc, Key Competitors 30
Vertex Pharmaceuticals Inc, Key Employees 31
Vertex Pharmaceuticals Inc, Subsidiaries 33

List Of Figures

List of Figures
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Vertex Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Vertex Pharmaceuticals Inc (VRTX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Vertex Pharmaceuticals Inc (Vertex) is a biotechnology company that carries out the discovery, development and commercialization of transformative drugs for the treatment of serious and life-threatening diseases. The company product

USD 250View Report

Vertex Pharmaceuticals Incorporated Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Vertex Pharmaceuticals Incorporated Company Profile is a detailed strategic and analytical report on Vertex Pharmaceuticals Incorporated. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200View Report

Alexza Pharmaceuticals Inc - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Alexza Pharmaceuticals Inc (Alexza), a wholly owned subsidiary of Ferrer Therapeutics Inc, focuses on the research, development and commercialization of novel, proprietary products for the treatment of acute central nervous

USD 250View Report

Ra Pharmaceuticals Inc (RARX) - Medical Equipment - Deals and Alliances Profile

Ra Pharmaceuticals Inc (Ra Pharmaceuticals) is a clinical stage biopharmaceutical company that develops therapeutics for the treatment of diseases caused due to uncontrolled activation of the complement system. Ra Pharmaceuticals

USD 250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Jul 2018
No. of Pages :76
Country :United States of America
Category :Company Profiles
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube